{"id":3532,"date":"2025-05-21T07:13:41","date_gmt":"2025-05-21T07:13:41","guid":{"rendered":"https:\/\/bacteromic.com\/?p=3532"},"modified":"2025-07-03T13:31:50","modified_gmt":"2025-07-03T13:31:50","slug":"scope-fluidics-after-q1-2025-focus-on-project-development","status":"publish","type":"post","link":"https:\/\/bacteromic.com\/en\/scope-fluidics-after-q1-2025-focus-on-project-development\/","title":{"rendered":"Scope Fluidics after Q1 2025: Focus on Project Development"},"content":{"rendered":"

Scope Fluidics \u2013\u00a0a life-science company listed on\u00a0the Warsaw Stock Exchange (GPW) that develops innovative technologies for the medical diagnostics and healthcare markets \u2013\u00a0held more than PLN 138 million in\u00a0cash and cash equivalents at\u00a0the close of\u00a0Q1 2025.<\/strong><\/p>\n

In the first quarter, the Group met the first of\u00a0its strategic targets (regarding the number of\u00a0projects and special-purpose vehicles) and is\u00a0now advancing three SPVs: BACTEROMIC, scheduled to\u00a0debut on\u00a0the European market this year, and two new companies spun out of\u00a0Scope Discovery \u2013\u00a0EDOCERA and HYBOLIC. Scope Fluidics plans to\u00a0intensify investments tied to\u00a0ongoing projects and business scaling.<\/strong><\/p>\n

\u201cThe opening months of\u00a0the year were devoted to\u00a0intensive planning and to\u00a0actions centered on\u00a0advancing our key projects. Our top priority is\u00a0BACTEROMIC \u2013\u00a0we are working hard to\u00a0make it\u00a0our next commercial success following Curiosity Diagnostics, which we\u00a0sold for a\u00a0total of\u00a0USD 130 million. We\u00a0are systematically enhancing the value of\u00a0the BACTEROMIC system, which delivers precise information on\u00a0the antibiotics most effective for treating bacterial infections. Early Access Program results confirmed the solution\u2019s readiness for commercialization. We\u00a0are pursuing certification under IVDR requirements, and in\u00a0May we\u00a0filed a\u00a0pre-submission with the U.S. FDA for the BACTEROMIC system with the Rapid UNI Panel. We\u00a0are also investing in\u00a0a\u00a0semi-automated production line for BACTEROMIC panels being developed in\u00a0partnership with an\u00a0NYSE-listed global industrial-technology leader. Over the coming months we\u00a0will further intensify work on\u00a0our flagship project and related key investments. Continuous investment in\u00a0our projects is\u00a0how we\u00a0execute our strategy \u2013\u00a0to sell our innovative solutions on\u00a0a\u00a0regular basis,\u201d<\/em>\u00a0said Piotr Garstecki, CEO of\u00a0Scope Fluidics.<\/strong><\/p>\n

In Q1\u00a0the Group achieved the first milestone of\u00a0the Scope Fluidics Development Strategy ahead of\u00a0schedule. The strategy envisaged that by\u00a0the end of\u00a02025 the Company would have at\u00a0least five new projects in\u00a0its portfolio, including at\u00a0least two structured as\u00a0SPVs.<\/p>\n

Scope Fluidics is\u00a0currently developing two new projects within SPVs: 1)\u00a0EDOCERA \u2013\u00a0a system designed for rapid diagnosis of\u00a0stroke onset; 2)\u00a0HYBOLIC \u2013\u00a0a system intended for early detection of\u00a0metabolic-syndrome risk, leading among other outcomes to\u00a0insulin resistance and type 2\u00a0diabetes, by\u00a0quantifying key biomarkers, including hormones.<\/p>\n

Project generation and early development are handled by\u00a0Scope Discovery \u2013\u00a0an in-house venture-studio organization responsible for creating and advancing new projects in\u00a0a\u00a0repeatable, structured model. As\u00a0of the end of\u00a0Q1 2025, 48\u00a0projects had been registered for evaluation within Scope Discovery: 17\u00a0have been closed, 13\u00a0are in\u00a0progress, and another 16\u00a0are awaiting assessment.<\/p>\n

Intensifying Investment in\u00a0a\u00a0Challenging Environment<\/strong><\/p>\n

At the end of\u00a0Q1 2025 the Group held more than PLN 138 million in\u00a0cash and cash equivalents (approximately PLN 116 million in\u00a0cash and bank balances and approximately PLN 22\u00a0million in\u00a0investment-fund units).<\/p>\n

\u201cWe currently allocate the bulk of\u00a0our capital-expenditure budget to\u00a0developing Bacteromic as\u00a0we prepare it\u00a0for a\u00a0potential M&A transaction. Investing in\u00a0advanced technologies is\u00a0a\u00a0long-term process that requires specialist knowledge, a\u00a0strong expert base, and prudent yet flexible financial management \u2013\u00a0an approach we\u00a0have followed for years. In\u00a0the face of\u00a0geopolitical and market uncertainty, maintaining a\u00a0strong cash position is\u00a0essential to\u00a0reinforce our negotiating stance and maximize value for stakeholders. We\u00a0are fully aware that sizable investments lie ahead, shaping the Company\u2019s future over the coming years. To\u00a0expand our financing options, we\u00a0have proposed that shareholders authorize the Management Board to\u00a0issue up\u00a0to 680 thousand new shares under authorized capital. We\u00a0are also analyzing other available options,\u201d<\/em>\u00a0noted Szymon Ruta, Vice President and CFO of\u00a0Scope Fluidics.<\/strong><\/p>\n

Management estimates that achieving Group Objectives for 2025\u20132027 will require total funding of\u00a0roughly PLN 240 million (including outlays already incurred since the start of\u00a02025).<\/p>\n

Without additional financing, the Group\u2019s current resources will support the gradual development of\u00a0projects until the end of\u00a0the first half of\u00a02027. However, fully realizing both the value-creation potential of\u00a0projects already under way within the Group (BACTEROMIC, EDOCERA, HYBOLIC) and the ability to\u00a0generate new projects that could be\u00a0pursued within new special-purpose vehicles will require additional funding.<\/p>\n

We have a\u00a0major opportunity ahead to\u00a0maximize the value of\u00a0the BACTEROMIC system \u2013\u00a0to obtain IVDR and FDA certifications and to\u00a0initiate sales. Delivering on\u00a0this plan will require additional funding that will, among other things, allow us\u00a0to scale production capacity. A\u00a0sale of\u00a0the Bacteromic company that is\u00a0advantageous for the Group also depends on\u00a0our maintaining a\u00a0secure negotiating position and sufficient flexibility regarding the terms of\u00a0cooperation with potential strategic and institutional investors,\u201d\u00a0<\/em>said Szymon Ruta, Vice President and Chief Financial Officer of\u00a0Scope Fluidics.<\/strong><\/p>\n

\u201cOur overarching goal is\u00a0to build a\u00a0dynamically growing global enterprise that consistently enhances shareholder value through new SPVs and regular strategic transactions. We\u00a0are therefore focusing on\u00a0investments that support operational scaling and long-term Group growth,\u201d\u00a0<\/em>added Piotr Garstecki.<\/strong><\/p>\n

European and U.S. Patents<\/strong><\/p>\n

In April of\u00a0this year, the European Patent Office granted Bacteromic a\u00a0patent that gives the company exclusive commercial rights to\u00a0the protected subject matter: a\u00a0method for predicting microbial growth or\u00a0inhibition in\u00a0a\u00a0phenotypic antibiotic-resistance test, a\u00a0system for rapid antibiotic-resistance testing, and the use of\u00a0a\u00a0deep neural network to\u00a0forecast such growth or\u00a0inhibition, Scope Fluidics reported.<\/p>\n

Additionally, in\u00a0May of\u00a0this year the United States Patent and Trademark Office granted Bacteromic a\u00a0patent that confers exclusive commercial rights in\u00a0the United States to\u00a0the protected incubation-segment geometry within a\u00a0microfluidic chip for microbiological testing. These tests cover both microbial identification and antibiotic-resistance assays, Scope Fluidics reported.<\/p>\n

The company also holds a\u00a0Chinese patent that grants exclusive commercial rights in\u00a0China to\u00a0the Bacteromic system\u2019s protected method for determining microbial drug resistance in\u00a0a\u00a0phenotypic test.<\/p>\n","protected":false},"excerpt":{"rendered":"

Scope Fluidics \u2013\u00a0a life-science company listed on\u00a0the Warsaw Stock Exchange (GPW) that develops innovative technologies for the medical diagnostics and healthcare markets \u2013\u00a0held more than PLN 138 million in\u00a0cash and cash equivalents at\u00a0the close of\u00a0Q1 2025. In the first quarter, the Group met the first of\u00a0its strategic targets (regarding the number of\u00a0projects and special-purpose vehicles) […]<\/p>\n","protected":false},"author":2,"featured_media":3537,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"iawp_total_views":0,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-3532","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/posts\/3532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/comments?post=3532"}],"version-history":[{"count":0,"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/posts\/3532\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/media\/3537"}],"wp:attachment":[{"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/media?parent=3532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/categories?post=3532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bacteromic.com\/en\/wp-json\/wp\/v2\/tags?post=3532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}